Quantcast
Channel: Phase – Global Regulatory Science
Viewing all articles
Browse latest Browse all 65

Galapagos’ bowel drug misses the mark in Phase II

0
0
Damian Garde Belgian biotech Galapagos is shutting down an ulcerative colitis program after its top prospect failed to make a difference in a Phase II trial, putting off plans for late-stage development as the company weighs whether to move forward in another disease. FierceBiotech News

Viewing all articles
Browse latest Browse all 65

Latest Images

Trending Articles





Latest Images